IOL Chemicals & Pharmaceuticals Q1 FY27 Investor Presentation Released
IOL Chemicals and Pharmaceuticals Limited reported Q1 FY27 revenue of ₹756.3 crore, up 37.1% YoY, with PAT at ₹64.5 crore, up 89.9% YoY. The company expects FY27 revenue growth of 15%-20% and EBITDA margins of 14%-15%. Key expansions include Paracetamol and Ethyl Acetate capacities. Exports are projected to contribute 25%-30% of revenue.
The announcement details significant financial performance improvements and strategic growth initiatives, which are highly material for investors and the company's market position.
The company reported strong year-on-year growth in revenue and profit, along with positive future guidance and ongoing capacity expansions, indicating a positive financial outlook.
IOL Chemicals and Pharmaceuticals Limited (IOLCP) has released its Investor Presentation for the first quarter of the financial year 2027, ending June 30, 2026. The presentation details the company's financial performance, business overview, historical performance, and future outlook.
In Q1 FY27, the company reported a Revenue from Operations of ₹756.3 crore, a significant 37.1% year-on-year increase. EBITDA stood at ₹111.7 crore, up 60.7% YoY, with an EBITDA margin of 14.6%. Profit After Tax (PAT) was ₹64.5 crore, marking a 89.9% YoY growth, with a PAT margin of 8.4%. For the full fiscal year 2026, Revenue from Operations was ₹2,319.1 crore, EBITDA was ₹290.4 crore, and PAT was ₹137.7 crore.
The company's business is diversified across Pharmaceuticals (29%) and Chemicals (71%). The presentation highlights a strategic shift towards value-added APIs and expansion in non-Ibuprofen segments. IOLCP has also made significant capacity expansions, including increasing Ethyl Acetate capacity to 1,20,000 MTPA and Acetic Anhydride to 32,000 MTPA in FY26. A new Paracetamol Unit-11 with a capacity of 10,800 MTPA was commissioned in FY25, and Clopidogrel capacity was enhanced to 240 MTPA.
Looking ahead, IOLCP has provided guidance for FY27, expecting revenue growth of 15%-20%, an EBITDA margin of 14%-15%, and an increase in export contribution to 25%-30%. The company also plans a capital expenditure of ₹200-250 crore. The presentation also emphasizes the company's commitment to ESG performance, receiving an Ecovadis Gold Medal and retaining the Responsible Care Logo for three consecutive years.
What to do with a filing like this
IOL Chemicals and Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by IOL Chemicals and Pharmaceuticals Limited. Read the original for the full detail.